全文获取类型
收费全文 | 36126篇 |
免费 | 2474篇 |
国内免费 | 138篇 |
专业分类
耳鼻咽喉 | 433篇 |
儿科学 | 937篇 |
妇产科学 | 601篇 |
基础医学 | 4449篇 |
口腔科学 | 676篇 |
临床医学 | 3414篇 |
内科学 | 8703篇 |
皮肤病学 | 562篇 |
神经病学 | 3218篇 |
特种医学 | 1184篇 |
外国民族医学 | 1篇 |
外科学 | 5082篇 |
综合类 | 457篇 |
一般理论 | 17篇 |
预防医学 | 2936篇 |
眼科学 | 783篇 |
药学 | 2634篇 |
1篇 | |
中国医学 | 62篇 |
肿瘤学 | 2588篇 |
出版年
2023年 | 163篇 |
2022年 | 252篇 |
2021年 | 629篇 |
2020年 | 385篇 |
2019年 | 621篇 |
2018年 | 742篇 |
2017年 | 553篇 |
2016年 | 603篇 |
2015年 | 656篇 |
2014年 | 1040篇 |
2013年 | 1527篇 |
2012年 | 2314篇 |
2011年 | 2385篇 |
2010年 | 1333篇 |
2009年 | 1212篇 |
2008年 | 2287篇 |
2007年 | 2520篇 |
2006年 | 2579篇 |
2005年 | 2501篇 |
2004年 | 2437篇 |
2003年 | 2351篇 |
2002年 | 2284篇 |
2001年 | 271篇 |
2000年 | 192篇 |
1999年 | 331篇 |
1998年 | 494篇 |
1997年 | 388篇 |
1996年 | 375篇 |
1995年 | 351篇 |
1994年 | 320篇 |
1993年 | 282篇 |
1992年 | 223篇 |
1991年 | 174篇 |
1990年 | 166篇 |
1989年 | 154篇 |
1988年 | 158篇 |
1987年 | 170篇 |
1986年 | 142篇 |
1985年 | 172篇 |
1984年 | 272篇 |
1983年 | 244篇 |
1982年 | 337篇 |
1981年 | 284篇 |
1980年 | 259篇 |
1979年 | 116篇 |
1978年 | 162篇 |
1977年 | 155篇 |
1976年 | 146篇 |
1975年 | 110篇 |
1974年 | 96篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
2.
3.
4.
5.
Agenesis of the Gallbladder Revisited Laparoscopically 总被引:1,自引:0,他引:1
Najam Azmat M.D. Kenneth R. Francis M.D. Neal Mandava M.D. Walter F. Pizzi M.D. 《The American journal of gastroenterology》1993,88(8):1269-1270
Gallbladder agenesis is an extremely rare disease. Necropsy incidence has been reported to be 0.016%. Failure lo locate the gallbladder at the time of a planned cholecystectomy can be very challenging. We report such a case during a laparoscopic cholecystectomy. The indication for surgery in these patients are complaints of gallbladder symptoms along with a false-positive ultrasound study. During exploration, an abnormal location of the gallbladder has to be excluded. Ectopic gallbladder locations include intrahepatic, lesser omentum, retroperitoneal, retrohepatic, within the falciform ligament, retroduodenal, and retrohepatic areas. Thorough exploration and cholangiography are essential. Embryologically, the gallbladder and cystic duct arise from the caudal portion of the hepatic bud. All of the previously reported cases of gallbladder agenesis have shown an absence of both the gallbladder and cystic duct. We report an embryological oddity wherein a patent cystic duct was found along with an agenetic gallbladder. This is the first case report of this finding, along with this being the first absent gallbladder discovered laparoscopically. 相似文献
6.
Shahid Husain Kenneth McCurry James Dauber Nina Singh Shimon Kusne 《The Journal of heart and lung transplantation》2002,21(3):354-359
BACKGROUND: Nocardia is responsible for infection in both normal and immunocompromised hosts. Organ transplant recipients are increasingly recognized as a sub-group of immunocompromised patients in whom nocardia is an important pathogen. The frequency of nocardia in organ transplant recipients varies between 0.7% and 3%. Nocardia infection has largely been reported in heart, kidney and liver transplant recipients. Presentations of nocardia in lung transplant recipients have been restricted primarily to case reports. The present study reviews the clinical and epidemiologic characteristics of nocardia infection in lung transplant recipients at our institution. METHODS: A retrospective cohort study of 473 lung transplant recipients from January 1991 to November 2000 was done at a university hospital. Patient demographics, immunosuppressive regimen at the time of isolation of nocardia species, use of trimethoprim-sulfamethoxazole for Pneumocystis carinii prophylaxis, rejection episodes in the preceding 6 months, concurrent pathogens, site of infection, radiologic findings and treatment and outcome were recorded. RESULTS: Nocardia infection was found in 2.1% (10 of 473) of our lung transplant recipients. Median time of onset was 34.1 months after transplantation. Nocardia species included N farcinica in 30% (3 of 10), N nova in 30% (3 of 10), N asteroides complex in 30% (3 of 10) and N brasiliensis in 10% (1 of 10) of patients. Post-transplant diabetes was present in 50% (5 of 10) of patients. The primary indication for lung transplantation was emphysema in 40% (4 of 10). Native lung involvement was noted in 75% (3 of 4) of patients with single lung transplant. Breakthrough nocardia infection were noted in 6 patients who were receiving trimethoprim-sulfamethoxazole prophylaxis for P carinii pneumonia; all breakthrough isolates remained susceptible to trimethoprim-sulfamethoxazole. Overall mortality was 40% (4 of 10). All patients (3 of 3) with infection due to N farcinica, except 1 (1 of 7) with infection due to other nocardia species, died. Seventy-five percent (3 of 4) of deaths were attributable to nocardia infection. CONCLUSIONS: Nocardia infection tended to involve the native lung in single lung transplant recipients. Trimethoprim-sulfamethoxazole for P carinii prophylaxis at the doses given was not protective against nocardiosis in these patients. Infection with N farcinica was associated with poor outcome. Thus, species identification and extended courses of antibiotics based on antimicrobial susceptibility testing are important in management of these patients. 相似文献
7.
8.
9.
Kenneth K. H. Chao BS Eric Cheung BS William B. Armstrong MD Brian J. F. Wong MD 《Otolaryngology--head and neck surgery》2002,126(6):593
Objective: The study goal was to compare the laser spot size created using reflective and refractive micromanipulators with a CO2 laser and to determine the sensitivity of spot size to laser power. Study Design and Setting: A CO2 laser and operating microscope (400-mm focal length) was coupled to either a reflective (Cassegrain-like) or refractive micromanipulator. Laser spot size was determined by measuring the region of ablation created by laser irradiation of wood (dry tongue depressors), exposed photographic film, and agar gel using optical micrometry. Laser power varied from 0.5 to 20 W with pulse durations of 0.1 and 0.5 second. Results: The reflective micromanipulator demonstrated overall smaller spot sizes for a given laser power and lower incremental change in spot size with increasing power. The reflective design demonstrated less sensitivity to increases in laser power. Conclusions: Micromanipulator optical design can result in significant differences in laser spot size. The reflective device used in this study demonstrated less sensitivity to increasing laser power. (Otolaryngol Head Neck Surg 2002;126:593-597.) 相似文献
10.
Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab, * etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab). 相似文献